Dr. Kelly has over 20 years of experience as a scientist and executive in the pharmaceutical industry starting as a medicinal chemist in 1990. After a successful early career developing LFA-1 antagonists, he was asked to lead Boehringer Ingelheim’s US-based medicinal chemistry department, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups. He joined CoMentis in 2010 as Chief Scientific Officer responsible for the Oklahoma City Research Center and the overall research portfolio. He was promoted to Chief Executive Officer in 2011.
Dr. Kelly completed his BS degree in chemistry at Rensselaer Polytechnic Institute and his Ph.D. degree in chemistry at the University of Texas at Austin. He completed postdoctoral work in natural products synthesis at Yale University and holds an MBA from New York University, Stern School of Business. Dr. Kelly is the co-author on over 25 scientific publications and serves on the College of Natural Sciences Advisory Council for the University of Texas.